# Palvella Therapeutics, Inc.: overview PVLA · Nasdaq · CIK 1583648 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/pvla.md) · [Financials](/companies/pvla/financials.md) · [Filings](/companies/pvla/filings.md) · [Insiders](/companies/pvla/insiders.md) Latest reported revenue: [$0](/filings/0001437749-24-034891.md) for Q3 FY2024, three months to 2024-09-30, from the 10-Q filed Nov 13, 2024 (XBRL us-gaap:Revenues, accession 0001437749-24-034891). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001437749-24-034891.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(3.94)](/filings/0001193125-25-276119.md) | not reported | [(0.74)](/filings/0001193125-26-210463.md) | [(0.86)](/filings/0001193125-26-331574.md) | [(1.03)](/filings/0001193125-25-276119.md) | not reported | [(1.20)](/filings/0001193125-26-210463.md) | [(1.52)](/filings/0001193125-26-331574.md) | | Free cash flow | $k | [(2,742) d](/filings/0001193125-25-276119.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [31.4](/filings/0001437749-23-008834.md) | [25.9](/filings/0001437749-24-010123.md) | [42.8](/filings/0001437749-24-010123.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(165.0%)](/filings/0001437749-23-008834.md) | [(167.8%)](/filings/0001437749-24-010123.md) | [(27.7%)](/filings/0000950170-25-047212.md) | not reported | not reported | | Net margin | % | [(145.6%)](/filings/0001437749-23-008834.md) | [(128.5%)](/filings/0001437749-24-010123.md) | [43.7%](/filings/0000950170-25-047212.md) | not reported | not reported | | Diluted EPS | $ per share | [(0.71)](/filings/0001583648-22-000016.md) | not reported | [2.17](/filings/0000950170-25-047212.md) | [(7.83)](/filings/0001193125-26-133372.md) | [(3.71)](/filings/0001193125-26-133372.md) | | Free cash flow | $m | [(8.6)](/filings/0001437749-23-008834.md) | [(61.0)](/filings/0001437749-24-010123.md) | [(13.9)](/filings/0000950170-25-047212.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/pvla/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2026-10-21 | [Goin Kathleen](/insiders/1912570.md) | Chief Operating Officer, Officer | Sale (S) | 607 | $126.1949 | $76.6k | [Form 4](/filings/0001104659-26-118466.md) | | 2026-10-21 | [Goin Kathleen](/insiders/1912570.md) | Chief Operating Officer, Officer | Sale (S) | 1,663 | $125.1645 | $208.1k | [Form 4](/filings/0001104659-26-118466.md) | | 2026-10-21 | [Goin Kathleen](/insiders/1912570.md) | Chief Operating Officer, Officer | Sale (S) | 2,043 | $123.6214 | $252.6k | [Form 4](/filings/0001104659-26-118466.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $173.5m | 1,135,406 | | Reduced −18,090 | | [JENNISON ASSOCIATES LLC](/funds/53417.md) | 2026-06-30 | $146.8m | 960,619 | | Added +320,008 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $140.3m | 918,357 | | Added +231,504 | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $134.8m | 882,400 | | Unchanged | | [First Light Asset Management, LLC](/funds/1600004.md) | 2026-06-30 | $118.0m | 771,901 | | Reduced −208,857 | | [BVF INC/IL](/funds/1056807.md) | 2026-06-30 | $102.8m | 672,789 | | Reduced −288,200 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $99.8m | 653,172 | | Added +194,173 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $78.5m | 513,794 | | Added +36,500 | | [FRONTIER CAPITAL MANAGEMENT CO LLC](/funds/351173.md) | 2026-06-30 | $73.2m | 478,833 | | Added +104,798 | | [FEDERATED HERMES, INC.](/funds/1056288.md) | 2026-06-30 | $66.2m | 433,015 | | Unchanged | ## Recent filings [All 807 filings](/companies/pvla/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-28 | 07:30 ET | [8-K](/filings/0001193125-26-435113.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-435113 | | 2026-08-04 | 07:51 ET | [10-Q](/filings/0001193125-26-331574.md) | Quarterly report, period 2026-06-30 | 0001193125-26-331574 | | 2026-08-04 | 07:30 ET | [8-K](/filings/0001193125-26-331556.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-331556 | | 2026-07-14 | 16:48 ET | [8-K](/filings/0001193125-26-303307.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-303307 | | 2026-06-30 | 07:36 ET | [8-K](/filings/0001104659-26-079087.md) | 5.02 Departure or appointment of officers or directors | 0001104659-26-079087 | | 2026-06-16 | 08:30 ET | [8-K](/filings/0001104659-26-074338.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001104659-26-074338 | | 2026-05-20 | 16:35 ET | [8-K](/filings/0001193125-26-232717.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-232717 | | 2026-05-15 | 07:30 ET | [8-K](/filings/0001193125-26-225317.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-225317 | | 2026-05-13 | 07:30 ET | [8-K](/filings/0001193125-26-220607.md) | 8.01 Other events | 0001193125-26-220607 | | 2026-05-07 | 09:09 ET | [8-K](/filings/0001193125-26-210605.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-210605 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-133372.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1583648 - Tickers: PVLA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 07:31 ET. No prices; not investment advice.